At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, medical director, Northwest Georgia Oncology Center, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.
“The number of new cancer cases and survivors are expected to rise,” Gould said. “Survivors will increase from 11.7 million in 2007 to 18 million in 2020. Patients are living longer, especially with multiple treatment options available—however, the new treatments are expensive.” Melanoma, for example, has seen a significant improvement in patient survival, especially after the checkpoint inhibitors arrived on the scene. “But these drugs come with a significant price tag,” Gould said.
Gould went on to share the findings of a Milliman report, commissioned by COA, that did a cost of care analysis to identify drivers of cancer care costs. “Hospitals—academic ones in particular, were identified as major cost drivers,” he said. “There’s a significant consolidation of practices with hospitals, and cost of care is definitely much higher in hospitals than in private practice.”
What is COA doing about this? Gould described the Oncology Medical Home (OMH) model, which was initiated by COA, as well as the associated accreditation program.
“We have been speaking about the OMH concepts across the country with various practices, and several institutions have been adopting this care model,” Gould said. OMH assures practices better value for the dollars spent, provide patients care at home, and is a path to cost savings, he added.
The OMH accreditation program helps validation of compliance standards, appropriate structures and processes, and the need to have an EHR, Gould told the audience. “Further, there are 5 domains of care that are the primary focus of the program, namely: patient engagement, expanded access, comprehensive team-based care, evidence-based medicine, and quality improvement projects,” Gould said. He then highlighted some of the nuances of the various domains:
“COA has multiple projects and has commissioned several studies to address these issues,” Gould said.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More